HEMOTAG Revenue

About HEMOTAG

At HEMOTAG, we're redefining heart care for the next decade—so we can all age gracefully and live longer, happier and healthier lives together. Heart disease is the world’s #1 killer—claiming more lives each year than all cancers and respiratory diseases combined, because once your disease gets acute to heart failure you have a less than 50% chance of making it past 5-years. Because early worsening is only detectable through invasive intracardiac procedures— which are expensive, risky, and out of reach for most. HEMOTAG delivers the industries first, intracardiac precision data non-invasively. To detect heart decompensation early—before symptoms appear—and enable timely intervention with a quick 30-second daily check. The award winning, easy-to-use, reusable wireless design enables accurate assessment. And the digital health solution offers actionable delivery at clinics, hospitals and home. HEMOTAG is backed by NIH, that have selected us as the “Innovative biotechnology company among the best of the best”. Over four years of clinical use and adoption by top health systems in the US, HEMOTAG continues to save lives. FDA registered in the U.S., with expansion plans nation-wide. We are seeking strategic partners to accelerate growth.

View contact profiles from HEMOTAG